Phase II study of Pemetrexed plus Bevacizumab (YCRG04) in exacerbation cases of Non-squamous Non-small cell lung cancer, previously treated with bevacizumab plus platinum-based chemotherapy. - Phase II study of PEM plus Bevacizumab in patients with NSCLC previously treated with bevacizumab plus platinum-based chemotherapy (YCRG-04).

Yokohama City University Medical Center0 个研究点目标入组 45 人开始时间: 2011年11月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Prior Pemetrexed treatment 2)History of hemoptysis(>=2.5ml) 3)History of severe drug allergy 4)Thrombosis 5)Active infection 6)Any other serious complication (severe heart disease, perforation of the digestive tract, uncontrollable diabetes or hypertension, gastrointestinal hemorrhage, paresis of intestine, illeus, interstinal lung disease etc.) 7)Prior radiotherapy to the chest or the more than 20% region of bone with hematopoietic capacity 8)Massive pleural or pericardial effusion, ascites *include patients if there is no accumulation within two weeks after dranage tube was removed. *exclude patients if pleurosclerosis was performed with anti-cancer drugs except OK-432 9)Inadequate interval after prior treatments *operation including exploratory or diagnostic thoracotomy within 4 weeks *palliative radiotherapy within 2 weeks *biopsy with incision and treatment for trauma (exclude patiente with unhealed wound) within 2 weeks *transfusion or use of hematopoietic factor within 2weeks. 10)Concomitant malignancy 11)Severe psychotic disorder 12)Pregnancy,Lactation,declined contraception 13)Inappropriate for this study judged by the attending physician

发起方